Adults 18 to 45, any sex, with Drug Mechanism or Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Comparison of Geometric Means of Cmax and AUC 0-last of Paracetamol Measured by the Novel Electrochemical Method With Mass-spectrometry in Capillary Whole Blood Samples.Primary· 1 day
Geometric mean values of the highest paracetamol concentrations (Cmax) and area under the curve (AUC) measured with the novel electrochemical method were compared with the 'gold standard' mass-spectrometry (control) from capillary whole blood samples. The data are presented as the ratio of geometric means to control, geometric coefficients of variation (as percentage) as a measure of dispersion.
Group
Value
95% CI
Cmax
1.03
± 21
AUC 0-last
1.17
± 29
Comparison of Geometric Means of Cmax and AUC 0-last of Paracetamol in Capillary With Venous Plasma (Control), Both Measured by Mass-spectrometry.Secondary· 12 hours
Geometric mean values of the highest paracetamol concentrations (Cmax) and area under the curve -calculations (AUC0-last) measured by mass-spectrometry were compared between capillary and plasma (control) to analyse paracetamol pharmacokinetics. The data are presented as ratio-to-control with geometric coefficients of variation (as percentage).
Group
Value
95% CI
Cmax
1.50
± 31
AUC 0-last
1.08
± 30
Sponsor's own description
The main objective is to assess whether a novel electrochemical tool is reliable in detecting concentration of paracetamol in fingerprick- , saline-, urine-, and serum samples. We will recruit 12 healthy volunteers aged 18-45. They will get 1 g oral paracetamol. Paracetamol concentration will be detected from abovementioned samples at timely intervals for 24 hours, analyzed with the novel electrochemical method and compared to gold standard mass-spectrometry analysis.
Despite of extensive use, the mechanism of action of parasetamol is not completely understood. The central serotonergic system may play a role. Endocannabinoid system is a group of lipid mediators, that possibly is involved in mediating paracetamol effect to the serotonergic system. Serum lipidomic assessment can be used to study endocannabinoid metabolics. In this study we will try to assess changes in endocannabinoid system by looking into serum lipidomics in order to understand the mechanism of action of paracetamol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg
· NA
· not yet recruiting
NCT07426744 — Antipyretic Therapy With and Without Cold Sponging
· NA
· not yet recruiting
NCT07104097 — Comparison Between 2 Techniques for Lumbar-ESPB
· NA
· not yet recruiting
NCT06920056 — A Study of BGM0504 in Overweight or Obese Participants
· Phase 1
· completed
NCT07002788 — Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery.
· NA
· active not recruiting
Other recruiting trials for Drug Mechanism
Currently open trials in the same condition.
NCT04659343 — TDM for Optimized Outcome in Patients With mRCC.
· recruiting
Other Johanna Kujala trials
Trials by the same sponsor.
NCT05167591 — Detection of Paracetamol Concentration in Patients Using Regular Medication- a Validation Study for a Novel Technique
· NA
· withdrawn
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johanna Kujala
Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04690673.